Epidemiology and Clinical Aspects of Malignant Pleural Mesothelioma

被引:35
|
作者
Brims, Fraser [1 ,2 ,3 ]
机构
[1] Curtin Univ, Curtin Med Sch, Perth, WA 6845, Australia
[2] Sir Charles Gairdner Hosp, Dept Resp Med, Perth, WA 6009, Australia
[3] Inst Resp Hlth, Natl Ctr Asbestos Related Dis, Perth, WA 6009, Australia
关键词
mesothelioma; asbestos; epidemiology; pleural disease; TO-LYMPHOCYTE RATIO; PROGNOSTIC-FACTORS; OPEN-LABEL; TALC PLEURODESIS; LUNG-CANCER; SOLUBLE MESOTHELIN; SERUM MESOTHELIN; PHASE-III; DIAGNOSIS; ASBESTOS;
D O I
10.3390/cancers13164194
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Simple Summary Mesothelioma is a cancer of the lining of the lungs caused by breathing in asbestos fibres. Asbestos was widely used in industry in the last century in most developed countries and is still present in many older buildings to this day. There is no known safe level of asbestos exposure. Symptoms of mesothelioma can include worsening breathlessness, chest pain and loss of weight. There is no cure, and the treatment of mesothelioma is limited, although there have been some recent improvements in therapy. Survival is very variable although most people live for around one year after diagnosis. Efforts to improve and maintain the quality of life for patients with mesothelioma remain a priority. Mesothelioma is a cancer predominantly of the pleural cavity. There is a clear association of exposure to asbestos with a dose dependent risk of mesothelioma. The incidence of mesothelioma in different countries reflect the historical patterns of commercial asbestos utilisation in the last century and predominant occupational exposures mean that mesothelioma is mostly seen in males. Modern imaging techniques and advances in immunohistochemical staining have contributed to an improved diagnosis of mesothelioma. There have also been recent advances in immune checkpoint inhibition, however, mesothelioma remains very challenging to manage, especially considering its limited response to conventional systemic anticancer therapy and that no cure exists. Palliative interventions and support remain paramount with a median survival of 9-12 months after diagnosis. The epidemiology and diagnosis of mesothelioma has been debated over previous decades, due to a number of factors, such as the long latent period following asbestos exposure and disease occurrence, the different potencies of the various forms of asbestos used commercially, the occurrence of mesothelioma in the peritoneal cavity and its heterogeneous pathological and cytological appearances. This review will describe the contemporary knowledge on the epidemiology of mesothelioma and provide an overview of the best clinical practice including diagnostic approaches and management.
引用
收藏
页数:15
相关论文
共 50 条
  • [21] Implementation of a molecular epidemiology approach to human pleural malignant mesothelioma
    Puntoni, R
    Filiberti, R
    Cerrano, PG
    Neri, M
    Andreatta, R
    Bonassi, S
    MUTATION RESEARCH-REVIEWS IN MUTATION RESEARCH, 2003, 544 (2-3) : 385 - 396
  • [22] PLEURAL MESOTHELIOMA - CLINICAL, PARACLINICAL AND EPIDEMIOLOGICAL ASPECTS
    CAILLARD, JF
    LAHOUTTE, C
    FRIMAT, P
    ROMON, M
    ARCHIVES DES MALADIES PROFESSIONNELLES DE MEDECINE DU TRAVAIL ET DE SECURITE SOCIALE, 1977, 38 (12): : 1040 - 1047
  • [23] Clinical features and epidemiology of malignant pleural mesothelioma. In west Glasgow 1987-1992.
    McLean, AN
    Patel, KR
    SCOTTISH MEDICAL JOURNAL, 1997, 42 (02) : 37 - 39
  • [24] CLINICAL ASPECTS OF MALIGNANT MESOTHELIOMA IN AUSTRALIA
    DRISCOLL, TR
    BAKER, GJ
    DANIELS, S
    LEE, J
    THOMPSON, R
    FERGUSON, DA
    LEIGH, J
    AUSTRALIAN AND NEW ZEALAND JOURNAL OF MEDICINE, 1993, 23 (01): : 19 - 25
  • [25] Malignant pleural mesothelioma
    Hughes, RS
    AMERICAN JOURNAL OF THE MEDICAL SCIENCES, 2005, 329 (01): : 29 - 44
  • [26] Malignant pleural mesothelioma
    Rao, D. Pragati
    Vijayan, Sruthy
    Vananjakar, Shashidhar S.
    Kumar, T. Prasanna
    BMJ CASE REPORTS, 2025, 18 (02)
  • [27] Malignant pleural mesothelioma
    Schouwink, H
    Baas, P
    Rutgers, ETH
    Zoetmulder, FAN
    EUROPEAN RESPIRATORY JOURNAL, 1999, 13 (03) : 706 - 706
  • [28] MALIGNANT PLEURAL MESOTHELIOMA
    FISHMAN, L
    JOURNAL OF THE MAINE MEDICAL ASSOCIATION, 1978, 69 (03): : 70 - 71
  • [29] MALIGNANT PLEURAL MESOTHELIOMA
    VAGLINI, M
    BOZZETTI, F
    VIGANOTTI, G
    TUMORI, 1978, 64 (05) : 529 - 534
  • [30] Malignant pleural mesothelioma
    Baas, P
    Schouwink, H
    Zoetmulder, FAN
    ANNALS OF ONCOLOGY, 1998, 9 (02) : 139 - 149